Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06335771

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.

Both groups will have:

* screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging [MRI] and magnetic resonance spectroscopy [MRS] scans) * Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies Participants with obesity will complete meetings with study team members for a weight loss intervention to achieve a 10% body weight loss.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Missouri School of Medicine

Columbia, Missouri, 65212, United States

Location status: Recruiting

Location contact

Bettina Mittendorfer

CONTACT

[email protected]

573-882-9377

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age: ≥18 but ≤70 years
  • not pregnant or breastfeeding
  • weight stable and sedentary before enrollment
  • no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity [MAO]-Type 2 Diabetes group)
  • no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)
  • participants must fulfil all of the following group-specific inclusion criteria below:

Lean group:

  • Body mass index (BMI) ≥18.5 but <25.0 kg/m2
  • Intrahepatic triglyceride (IHTG) content <5%
  • fasting blood glucose concentration: <100 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl
  • Hemoglobin A1C (HbA1c) <5.7 %

Metabolically normal obesity (MNO) group:

  • BMI ≥30.0 but <45.0 kg/m2
  • IHTG content <5%
  • fasting blood glucose concentration: <100 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl
  • HbA1c <5.7 %

Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:

  • BMI ≥30.0 but <45.0 kg/m2
  • IHTG content >7.5%
  • fasting blood glucose concentration: ≥100 but <126 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but <200 mg/dl
  • HbA1c: ≥5.7 but <6.4 %

MAO-type 2 diabetes group:

  • BMI ≥30.0 but <45.0 kg/m2
  • clinical diagnosis of type 2 diabetes or fasting blood glucose concentration >126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge>200 mg/dl or HbA1c >6.4 % without medication if not diagnosed and medically treated for diabetes

Exclusion criteria

  • Individuals that do not meet all inclusion Criterion

Treatment and study plan

Dietary consultation weight loss intervention

Other

Participants will meet with a member of the study team biweekly for about 6 months.

Primary outcomes

  1. Insulin sensitivity assessed as insulin-mediated glucose disposal during a hyperinsulinemic-euglycemic clamp procedure.

    Time frame: up to 6 months after the intervention

  2. 24-hour plasma glucose concentration

    Time frame: up to 6 months after the intervention

  3. Macrophage isolation in adipose tissue biopsy

    Time frame: up to 6 months after the intervention

    macrophage gene expression using RNA sequencing and fluorescent activated cell sorting (FACS)

  4. Macrophage isolation in skeletal muscle tissue

    Time frame: up to 6 months after the intervention

    macrophage gene expression using RNA sequencing and fluorescent activated cell sorting (FACS)

Study contacts

Contact information is provided by the study sponsor or research team.

Aman Pritish Aher

CONTACT

[email protected]

Heather McHatton

CONTACT

[email protected]

(573) 882-7619

Sponsors and collaborators

Lead sponsor

Bettina Mittendorfer

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Institutes of Health (NIH)
  • Washington University School of Medicine

Registry information

Official study title

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity-Associated Diseases

Acronym: ATM

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Mar 28, 2024
Registry last updated
Jul 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.